Bank of New York Mellon Corp increased its holdings in shares of Inogen, Inc (NASDAQ:INGN) by 4.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 293,070 shares of the medical technology company’s stock after purchasing an additional 13,160 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.42% of Inogen worth $27,964,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Inogen by 145,976.1% during the 1st quarter. BlackRock Inc. now owns 2,110,800 shares of the medical technology company’s stock worth $163,711,000 after acquiring an additional 2,109,355 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Inogen by 166.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 196,886 shares of the medical technology company’s stock worth $18,786,000 after acquiring an additional 122,913 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Inogen during the 1st quarter worth approximately $9,139,000. Marshall Wace North America L.P. bought a new stake in shares of Inogen during the 1st quarter worth approximately $9,139,000. Finally, FMR LLC lifted its stake in shares of Inogen by 56.2% during the 1st quarter. FMR LLC now owns 324,200 shares of the medical technology company’s stock worth $25,145,000 after acquiring an additional 116,600 shares during the last quarter.
A number of brokerages recently issued reports on INGN. Piper Jaffray Companies reissued a “hold” rating and set a $90.00 price target on shares of Inogen in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and set a $108.00 price objective on shares of Inogen in a report on Friday, September 1st. BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 8th. Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, J P Morgan Chase & Co raised their price objective on Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Inogen currently has an average rating of “Buy” and a consensus target price of $91.33.
In other Inogen news, EVP Alison Bauerlein sold 6,667 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $92.64, for a total value of $617,630.88. Following the transaction, the executive vice president now owns 15,000 shares in the company, valued at approximately $1,389,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $103.23, for a total transaction of $258,075.00. Following the completion of the transaction, the executive vice president now owns 6,964 shares in the company, valued at approximately $718,893.72. The disclosure for this sale can be found here. Insiders have sold a total of 62,467 shares of company stock worth $5,790,090 in the last 90 days. Company insiders own 5.31% of the company’s stock.
Shares of Inogen, Inc (NASDAQ INGN) opened at 104.49 on Wednesday. The firm has a market cap of $2.17 billion, a PE ratio of 90.70 and a beta of 1.02. Inogen, Inc has a 12 month low of $50.24 and a 12 month high of $104.88. The firm’s 50-day moving average price is $95.08 and its 200-day moving average price is $86.66.
Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period in the previous year, the company earned $0.25 EPS. Inogen’s revenue for the quarter was up 17.4% on a year-over-year basis. Analysts expect that Inogen, Inc will post $1.21 earnings per share for the current year.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.